Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRELUDE: CNTO 2476 in Geographic Atrophy Secondary to AMD
NCT02659098Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2015
- Primary completion
- Jun 2019
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of palucorcel in geographic atrophy (GA), age-related macular degeneration (AMD), sponsored by Janssen Pharmaceutical. Started Dec 2015; status: completed.
02
Drugs
palucorcel
03
Conditions
geographic atrophy (GA)age-related macular degeneration (AMD)
Beyond the preview
Go deeper on NCT02659098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02659098.